| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ... The Lancet 379 (9816), 633-640, 2012 | 1645 | 2012 |
| Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib … R Salgado, C Denkert, C Campbell, P Savas, P Nuciforo, C Aura, ... JAMA oncology 1 (4), 448-455, 2015 | 642 | 2015 |
| PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ... Oncogene 30 (22), 2547-2557, 2011 | 634 | 2011 |
| PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ... Cancer discovery 2 (11), 1036-1047, 2012 | 632 | 2012 |
| Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer A Juvekar, LN Burga, H Hu, EP Lunsford, YH Ibrahim, J Balmañà, ... Cancer discovery 2 (11), 1048-1063, 2012 | 474 | 2012 |
| USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma PJA Eichhorn, L Rodón, A Gonzàlez-Juncà, A Dirac, M Gili, ... Nature medicine 18 (3), 429-435, 2012 | 447 | 2012 |
| Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle L De Mattos-Arruda, B Weigelt, J Cortes, HH Won, CKY Ng, P Nuciforo, ... Annals of oncology 25 (9), 1729-1735, 2014 | 429 | 2014 |
| RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, ... Annals of Oncology 29 (5), 1203-1210, 2018 | 406 | 2018 |
| Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ... Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011 | 389 | 2011 |
| PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ... Science translational medicine 7 (283), 283ra51-283ra51, 2015 | 373 | 2015 |
| mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ... Science translational medicine 5 (196), 196ra99-196ra99, 2013 | 324 | 2013 |
| A RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation M Castroviejo‐Bermejo, C Cruz, A Llop‐Guevara, S Gutiérrez‐Enríquez, ... EMBO molecular medicine 10 (12), e9172, 2018 | 264 | 2018 |
| PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2–Targeted Therapies in Breast Cancer IJ Majewski, P Nuciforo, L Mittempergher, AJ Bosma, H Eidtmann, ... Journal of Clinical Oncology 33 (12), 1334-1339, 2015 | 258 | 2015 |
| Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2–positive breast tumors coexpressing the truncated p95HER2 receptor M Scaltriti, S Chandarlapaty, L Prudkin, C Aura, J Jimenez, PD Angelini, ... Clinical cancer research 16 (9), 2688-2695, 2010 | 185 | 2010 |
| Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy C García-García, YH Ibrahim, V Serra, MT Calvo, M Guzmán, J Grueso, ... Clinical cancer research 18 (9), 2603-2612, 2012 | 181 | 2012 |
| First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus … J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, C Aura, E De Azambuja, ... Cancer Research 70, 2010 | 165 | 2010 |
| Insulin-like growth factor-I and cancer risk YH Ibrahim, D Yee Growth hormone & IGF research 14 (4), 261-269, 2004 | 162 | 2004 |
| RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer V Serra, PJA Eichhorn, C García-García, YH Ibrahim, L Prudkin, ... The Journal of clinical investigation 123 (6), 2551-2563, 2013 | 155 | 2013 |
| The tumor suppressor FLCN mediates an alternate mTOR pathway to regulate browning of adipose tissue S Wada, M Neinast, C Jang, YH Ibrahim, G Lee, A Babu, J Li, A Hoshino, ... Genes & development 30 (22), 2551-2564, 2016 | 134 | 2016 |
| The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells MA Becker, YH Ibrahim, X Cui, AV Lee, D Yee Molecular endocrinology 25 (3), 516-528, 2011 | 129 | 2011 |
